SGLT2 Inhibitors in Management of Severe Hypomagnesemia in Patients Without Diabetes: A Report of 4 Cases
Shah CV, Hammad N, Bhasin-Chhabra B, Rashidi A
Kidney medicine · 21 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Case report (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Authors
- At least one author declares a financial tie to industry
Based on full-text disclosure statement.
Publication
- Published
- 2023-07-01 · Kidney Med · vol. 5 · issue 9 · p. 100697
- Publisher
- Elsevier BV
- Cited
- 28 citations · more than 93% of similar papers · 3.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 25 works
- Access
- Open access (journal) · CC-BY-NC-ND
- Research areas
- Magnesium in Health and Disease · Diabetes Treatment and Management · Restless Legs Syndrome Research
- Keywords
- Hypomagnesemia, Medicine, Refractory (planetary science), Diabetes mellitus, Magnesium, Magnesium deficiency (plants), Internal medicine, Glycemic, Population, Gastroenterology, Endocrinology, Chemistry
4 authors
From US
- Chintan Vimalkumar Shah · correspondingUniversity of Florida
- Nour HammadUniversity Hospitals of Cleveland
- Bhavna BhasinMayo Clinic in Arizona
- Arash RashidiUniversity Hospitals of Cleveland
Abstract
Sodium/glucose cotransporter 2 (SGLT2) inhibitors have demonstrated a class effect in improving serum magnesium levels in patients with diabetes. Additionally, recent reports have shown their promising beneficial effects in the treatment of refractory hypomagnesemia in patients with diabetes. However, their role in treating hypomagnesemia in patients without diabetes remains unexplored. Here, we report 4 cases of severe and refractory hypomagnesemia that showed dramatic improvement after initiating SGLT2 inhibitors in patients without diabetes. Case 1 had calcineurin inhibitor-associated severe hypomagnesemia. Cases 2, 3, and 4 had refractory hypomagnesemia associated with platinum-based chemotherapy with or without gastrointestinal losses. Case 1 was able to withdraw from high-dose oral magnesium supplementation. Cases 2 and 3 achieved independence from intravenous magnesium supplementation, whereas case 4 had decreased intravenous magnesium requirements. All the cases demonstrated sustainably improved serum magnesium levels. Withdrawal of SGLT2 inhibitors in case 4 resulted in worsening serum magnesium levels and intravenous magnesium requirements. The extraglycemic benefit of this group of medications not only suggests the need for further studies to better understand the effect of SGLT2 inhibitors on magnesium homeostasis but also supports expanded use in a larger patient population.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.